Free tool
FAERS Monitor: Leukine
Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations
Reports naming BLA 103362 or its brand name (Leukine, Sargramostim). Reports on generic versions are filed under their own applications.
Reports
1,730
Serious
1,272
74% of reports
Hospitalization
581
Death reported
255
Any cause; not necessarily from the drug
Most reported reactions
MedDRA preferred terms.
- pyrexia158
- off label use155
- nausea128
- pain113
- hypotension111
- dyspnoea110
- fatigue94
- diarrhoea87
- death84
- vomiting83
- dizziness63
- chills57
- dehydration57
- syncope54
- febrile neutropenia52
Reports by year received
View as table
| Year | Reports |
|---|---|
| 2004 | 40 |
| 2005 | 47 |
| 2006 | 78 |
| 2007 | 65 |
| 2008 | 167 |
| 2009 | 58 |
| 2010 | 68 |
| 2011 | 128 |
| 2012 | 142 |
| 2013 | 92 |
| 2014 | 58 |
| 2015 | 57 |
| 2016 | 78 |
| 2017 | 67 |
| 2018 | 72 |
| 2019 | 48 |
| 2020 | 39 |
| 2021 | 107 |
| 2022 | 76 |
| 2023 | 62 |
| 2024 | 45 |
| 2025 | 68 |
| 2026 | 66 |
Disproportionality screen
Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,052,429 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.
| Reaction | Reports | PRR | 95% CI lower | Chi-squared |
|---|---|---|---|---|
| febrile neutropeniaSignal | 52 | 9.5 | 7.3 | 390 |
| hypotensionSignal | 111 | 6.7 | 5.6 | 541 |
| syncopeSignal | 54 | 6.6 | 5.0 | 250 |
| chillsSignal | 57 | 5.9 | 4.6 | 229 |
| pyrexiaSignal | 158 | 5.6 | 4.8 | 595 |
| dehydrationSignal | 57 | 5.2 | 4.0 | 190 |
| dyspnoeaSignal | 110 | 2.4 | 2.0 | 87 |
| painSignal | 113 | 2.2 | 1.9 | 78 |
| off label useSignal | 155 | 2.2 | 1.9 | 99 |
| vomitingSignal | 83 | 2.1 | 1.7 | 51 |
| nausea | 128 | 2.0 | 1.7 | 62 |
| diarrhoea | 87 | 1.6 | 1.3 | 22 |
| dizziness | 63 | 1.5 | 1.2 | 12 |
| fatigue | 94 | 1.5 | 1.2 | 14 |
| death | 84 | 1.2 | 1.0 | 2 |
A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.